Risk factor
Weak & very vulnerable to price shocks
Profitability factor
Very low or no dividends
About
Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN (freeze-dried) that has...
Company Valuation
Considering past and projected metrics, the stock is slightly 'cheaper' than its peers. Specifically, the stock is fairly valued on P/E, neutral on EV/EBITD.
Target Price
The average target price of BAVA.CO is 250 and suggests 42% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incr
Buy
Sell